Denopamine, a β1-adrenergic agonist, prolongs survival in a murine model of congestive heart failure induced by viral myocarditis: Suppression of tumor necrosis factor-α production in the heart

Journal of the American College of Cardiology

Volumn 32, Issue 3, 1998, Pages 808-815

  Nishio, Ryosuke ^a   Matsumori, Akira ^a   Shioi, Tetsuo ^a   Wang, Weizhong ^a   Yamada, Takehiko ^a   Ono, Koh ^a   Sasayama, Shigetake ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; DENOPAMINE; METOPROLOL; TUMOR NECROSIS FACTOR ALPHA; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CARDIOTONIC AGENT; ETHANOLAMINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; ENCEPHALOMYOCARDITIS VIRUS; HEART MUSCLE INJURY; HISTOPATHOLOGY; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SURVIVAL TIME; TIME; VIRUS MYOCARDITIS; ANIMAL; CULTURE TECHNIQUE; DBA MOUSE; HEART MUSCLE; METABOLISM; MYOCARDITIS; PATHOLOGY; VIRUS INFECTION;

ADRENERGIC BETA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; CARDIOTONIC AGENTS; CARDIOVIRUS INFECTIONS; CULTURE TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENCEPHALOMYOCARDITIS VIRUS; ETHANOLAMINES; HEART FAILURE, CONGESTIVE; MALE; METOPROLOL; MICE; MICE, INBRED DBA; MYOCARDITIS; MYOCARDIUM; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031596213     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(98)00314-3     Document Type: Article

References (59)

1. Kereiakes D.J., Parmley W.W. Myocarditis and cardiomyopathy. Am Heart J. 108:1984;1318-1326.
2. Abelmann W.H. Virus and the heart. Circulation. 44:1971;950-956.
3. Woodruff J.F. Viral myocarditis A review . Am J Pathol. 101:1980;425-484.
4. Packer M. Treatment of chronic heart failure. Lancet. 340:1992;92-95.
5. Sasayama S. What do the newer inotropic drugs have to offer? Cardiovasc Drugs Ther. 6:1992;15-18.
6. Matsui S., Matsumori A., Matoba Y., et al. Treatment of virus-induced myocardial injury with a novel immunomodulating agent, vesnarinone Suppression of natural killer cell activity and tumor necrosis factor-alpha production . J Clin Invest. 94:1994;1212-1217.
7. Inamasu M., Totsuka T., Ikeo T., et al. β1-adrenergic selectivity of the new cardiotonic agent denopamine in its stimulating effects on adenylate cyclase. Biochem Pharmacol. 36:1987;1947-1954.
8. Ikeo T., Nagao T., Suzuki T., Yabana H., Nakajima H. Cardiovascular effects and plasma levels of denopamine (TA-064), a new positive inotropic agent, in chronically instrumented dogs. Jpn J Pharmacol. 39:1985;191-199.
9. Matsumori A., Kawai C. An experimental model for congestive heart failure after encephalomyocarditis virus myocarditis in mice. Circulation. 65:1982;1230-1235.
10. Matsumori A., Kawai C. An animal model of congestive (dilated) cardiomyopathy dilatation and hypertrophy of the heart in the chronic stage in DBA/2 mice with myocarditis caused by encephalomyocarditis virus . Circulation. 66:1982;355-360.
11. Lane J.R., Neumann D.A., Lafond-Walker A., et al. Interleukin 1 or tumor necrosis factor can promote coxsackie B3-induced myocarditis in resistant B10.A mice. J Exp Med. 175:1992;1123-1129.
12. Yamada T., Matsumori A., Sasayama S. Therapeutic effect of anti-tumor necrosis factor-alpha antibody on the murine model of viral myocarditis induced by encephalomyocarditis virus. Circulation. 89:1994;846-851.
13. Barry W.H. Mechanisms of immune-mediated myocyte injury. Circulation. 89:1994;2421-2432.
14. Sasayama S. Immune modulation of cardiac function a new frontier . J Cardiac Fail. 5:1995;331-335.
15. Packer M. Is tumor necrosis factor an important neurohormonal mechanism in chronic heart failure? Circulation. 92:1995;1379-1382.
16. Mann D.L., Young J.B. Basic mechanisms in congestive heart failure Recognizing the role of proinflammatory cytokines . Chest. 105:1994;897-904.
17. Matsumori A., Yamada T., Suzuki H., et al. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J. 72:1994;561-566.
18. Bristow M.R. Tumor necrosis factor-α and cardiomyopathy. Circulation. 97:1998;1340-1341.
19. Bryant D., Becker L., Richardson J., et al. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-α Circulation. 97:1998;1375-1381.
20. Biykem B., Kribbs S.B., Clubb F.J., et al. Pathophysiologically relevant concentrations of tumor necrosis factor-α promote progressive left ventricular dysfunction and remodeling in rats. Circulation. 97:1998;1382-1391.
21. Morikawa N., Higuchi K., Tsukamoto T., et al. Development of a simple analytical method to determine the serum concentration of denopamine by high performance liquid chromatography with electrochemical detection and its clinical application. Yakugaku Zasshi. 109:1989;858-864.
22. Ozaki N., Bito K., Kinoshita M., Kawakita S. Effects of a cardiotonic agent, TA-064, on isolated canine cerebral, coronary, femoral, mesenteric, and renal arteries. J Cardiovasc Pharmacol. 5:1983;818-821.
23. Pizarro T.T., Malinowska K., Kovacs E.J., et al. Induction of TNF-α and TNF-β gene expression in rat cardiac transplants during allograft rejection. Transplantation. 56:1993;399-404.
24. Sekido N., Mukaida N., Harada A., et al. Prevention of lung reperfusion injury in rabbits by a monoclonal antibody against interleukin-8. Nature. 365:1993;654-657.
25. Torre-Amione G., Kapadia S., Lee J., et al. Tumor necrosis factor-α and tumor necrosis factor receptors in the failing human heart. Circulation. 93:1996;704-711.
26. Fauth U., Schlechtriemen T., Heinrichs W., et al. The measurement of enzyme activities in the resting human polymorphonuclear leukocyte-critical estimate of a method. Eur J Clin Chem Clin Biochem. 31:1993;5-16.
27. Kino M., Hirota Y., Yamamoto S., et al. Cardiovascular effects of a newly synthesized cardiotonic agent (TA-064) on normal and diseased hearts. Am J Cardiol. 51:1983;802-810.
28. Cohn J.N. Inotropic therapy for heart failure paradise postponed . N Engl J Med. 320:1989;729-731.
29. Eisner D.A., Smith T.W. The Na-K pump and its effectors in cardiac muscle. Fozzard H.A., Haber E., Jennings R.B., Katz A.M., Morgan H.F. The Heart and Cardiovascular System. 1991;863-902 Raven Press, New York.
30. Smith T.W. Digitalis mechanisms of action and clinical use . N Engl J Med. 318:1988;358-365.
31. Colucci W.S., Wright R.F., Braunwald E. New positive inotropic agents in the treatment of congestive heart failure Mechanisms of action and recent clinical developments. II . N Engl J Med. 314:1986;349-358.
32. Feldman AM, Bristow MR, Parmley WW, et al., for the vesnarinone study group. Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med 1993;329:149-55.
33. Sonnenblick E.H., Frishman W.H., LeJemtel T.H. Dobutamine a new synthetic cardioactive sympathetic amine . N Engl J Med. 300:1979;17-22.
34. Bristow M.R., Hershberger R.E., Port J.D., et al. β-adrenergic pathways in non-failing and failing human ventricular myocardium. Circulation. 82:1990;I12-I5.
35. Katz A.M. Cardiomyopathy of overload A major determinant of prognosis in congestive heart failure . N Engl J Med. 322:1990;100-110.
36. Braunwald E. Mechanism of action of calcium-channel-blocking agents. N Engl J Med. 307:1982;1618-1627.
37. Xamoterol in severe heart failure. Lancet. 336:1990;1-6.
38. Thormann J., Kramer W., Kindler M., et al. Analysis of the efficacy of the new cardiotonic agent TA-064. Am Heart J. 110:1985;426-438.
39. Takarada A., Yokota Y., Fukuzaki H. Effects of a new cardiotonic agent, "TA-064," in patients with dilated cardiomyopathy-relationship between cardiac effect of TA-064 and severity of myocardial lesion. Jpn Circ J. 51:1987;251-258.
40. Satoh Y., Taniguchi K., Koike A., et al. Short-term effects of denopamine on anaerobic threshold and related parameters in patients with chronic heart failure a double-blind crossover study . Clin Pharmacol Ther. 53:1993;562-569.
41. Ikeo T., Nagao T., Murata S., et al. Cardiovascular effects of the new positive inotropic agent denopamine with special reference to species difference and the effect on failing heart. Arzneimittelforschung. 36:1986;1063-1068.
42. Sato T., Imanishi K., Arita M. Positive inotropic effect of TA-064 (denopamine), a new cardiotonic agent, in guinea pig papillary muscle in comparison with isoproterenol and ouabain. Jpn Pharmacol Ther. 13:1985;5727-5736.
43. Ikeo T., Nagao T. Effects of denopamine (TA-064), a new positive inotropic agent, on myocardial oxygen consumption and left ventricular dimension in anesthetized dogs. Jpn J Pharmacol. 39:1985;179-189.
44. Yabana H., Naito K., Nagao T. Effect of chronic administration of denopamine (TA-064), a new positive inotropic agent, on cardiac response of rats to denopamine. Jpn J Pharmacol. 42:1986;87-97.
45. 1-adrenoceptor blocking action of denopamine in isolated rabbit aorta. J Cardiovasc Pharmacol. 17:1991;440-444.
46. Talmadge J., Scott R., Castelli P., et al. Molecular pharmacology of the b-adrenergic receptor on THP-1 cells. Int J Immunopharmacol. 15:1993;219-228.
47. van der Poll T., Jansen J., Endert E., et al. Noradrenaline inhibits lipopolysaccharide-induced tumor necrosis factor and interleukin 6 production in human whole blood. Infect Immun. 62:1994;2046-2050.
48. Spengler R.N., Allen R.M., Remick D.G., et al. Stimulation of a-adrenergic receptor augments the production of macrophage-derived tumor necrosis factor. J Immunol. 145:1990;1430-1434.
49. Spengler R.N., Chensue S.W., Giacherio D.A., et al. Endogenous norepinephrine regulates tumor necrosis factor-α production from macrophages in vitro. J Immunol. 152:1994;3024-3031.
50. Severn A., Rapson N.T., Hunter C.A., Liew F.Y. Regulation of tumor necrosis factor production by adrenaline and b-adrenergic agonists. J Immunol. 148:1992;3441-3445.
51. Tracey K.J., Vlassara H., Cerami A. Cachectin/tumour necrosis factor. Lancet. 1:1989;1122-1126.
52. Motulsky H.J., Insel P.A. Adrenergic receptors in man direct identification, physiologic regulation, and clinical alterations . N Engl J Med. 307:1982;18-29.
53. Borg K.O., Fellenius E., Johansson R., Wallborg M. Pharmacokinetic studies of metoprolol-(3H) in the rat and the dog. Acta Pharmacol Toxicol. 36:(suppl V):1975;104-115.
54. Levine B., Kalman J., Mayer L., Fillit H.M., Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 323:1990;236-241.
55. McMurray J., Abdullah I., Dargie H.J., Shapiro D. Increased concentrations of tumour necrosis factor in "cachectic" patients with severe chronic heart failure. Br Heart J. 66:1991;356-358.
56. Dutka D.P., Elborn J.S., Delamere F., et al. Tumor necrosis factor-α in severe congestive cardiac failure. Br Heart J. 70:1993;141-143.
57. Pagani F.D., Baker L.S., Hsi C., et al. Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosis factor-α in conscious dogs. J Clin Invest. 90:1992;389-398.
58. Gulick T., Chung M.K., Pieper S.J., et al. Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte β-adrenergic responsiveness. Proc Natl Acad Sci USA. 86:1989;6753-6757.
59. Yokoyama T., Vaca L., Rossen R.D., et al. Cellular basis for the negative inotropic effects of tumor necrosis factor-α in the adult mammalian heart. J Clin Invest. 92:1993;2303-2312.